Search
Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalIt is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
Synonyms: 1-(2-Tetrahydrofuryl)-5-fluorouracilInternational brands: ESUEEW AN T, Ai YiUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsDegarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalChemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Reduction in testosterone is important in treating men with advanced prostate cancer.
Products: FIRMAGON ®80MG, FIRMAGON ® 120MGGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersTioguanine Action Pathway
smpdb.ca/view/SMP0126656Drug actionAn overdose of tioguanine may result in symptoms like nausea, vomiting, malaise, hypotension, and diaphoresis. … Tioguanine is indicated for remission induction and remission consolidation in the treatment of acute nonlymphocytic leukemias.
Deep partial-thickness thermal burn
go.drugbank.com/conditions/DBCOND0106398Palovarotene
go.drugbank.com/drugs/DB05467ApprovedFibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. … [A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersAcepromazine
go.drugbank.com/drugs/DB01614InvestigationalVet approvedAcepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.
Categories: Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, 3-RingSynonyms: 1-[10-(3-dimethylamino-propyl)-10H-phenothiazin-2-yl]-ethanone, 10-(3-dimethylaminopropyl)phenothiazine-3-ethyloneDavamotecan pegadexamer
go.drugbank.com/drugs/DB05899InvestigationalEP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].
Categories: Compounds used in a research, industrial, or household settingDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation.
Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index